The Open Access journal of @myESMO dedicated to oncology research
Joined September 2015
- Tweets 2,706
- Following 399
- Followers 7,744
- Likes 114
454 Photos and videos
Jun 10
Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal mts: a large-scale multicenter retrospective study (FURMO-LM) in @ESMO_Open. Potential of combination therapies in this difficult population. esmoopen.com/article/S2059-7…
2
12
1,117
Jun 10
Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer in @ESMO_Open. No benefit of scalp cooling in terms of hair preservation or quality of life.G2 alopecia primary reason for scalp cooling discontinuation. esmoopen.com/article/S2059-7…
1
27
50
25,748
Jun 10
Safety analyses of the INAVO120 randomised ph III trial of inavolisib or placebo with palbociclib–fulvestrant in pts with PIK3CA-mutated, HR , HER2-, endocrine-resistant advanced BC in @ESMO_Open. Consistent, manageable & tolerable safety profile. esmoopen.com/article/S2059-7…
9
13
1,647
Jun 10
Impact of treatment discontinuation among patients with MSI or MRD metastatic CRC treated with immune checkpoint inhibitors in @ESMO_Open. Early discontinuation of ICIs in patients without progression did not compromise PFS or OS esmoopen.com/article/S2059-7…
1
27
53
4,355
Apr 27
First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies in @ESMO_Open. Most common TRAES: IRRs (n:14; 7 of G3), pyrexia, myalgia, rash. SD as best response in 39.3% of pts. esmoopen.com/article/S2059-7…
1
17
30
4,907
Apr 27
Compartment-specific immune and tumor markers associated with clinical outcomes in pts with & without sarcomatoid/rhabdoid RCC treated with ipi & nivo in @ESMO_Open. Better outcomes in PD-L1 high. Increased neutrophils infiltration in sarc/rhabd. esmoopen.com/article/S2059-7…
2
7
15
2,445
Apr 27
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell RCC: results from a global RWE study in @ESMO_Open. Large retrospective cohort, rechallenge 6 months or more after previous ICI led to improved PFS & OS. esmoopen.com/article/S2059-7…
13
38
4,375
Apr 3
Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study in @ESMO_Open.Improved PFS & DCR with FTD-TPI Bev, including KRAS p.G12C mCRC. esmoopen.com/article/S2059-7…
1
25
60
5,547
Apr 3
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma in @ESMO_Open. 1yr & 2yrs OS rate >70% & >50%, pure WD better PFS, potential prognostic role of CDH18 IHC. esmoopen.com/article/S2059-7…
1
10
20
2,369
Apr 3
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia in @ESMO_Open. 969 pts, 6 studies: consistent safety profile, some differences between NA/Europe and Asia. esmoopen.com/article/S2059-7…
23
49
5,020
Mar 19
A randomized Ph3 clinical trial of weekly vs tri-weekly cisplatin-based CRT for LA cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study in @ESMO_Open.No survival differences, better tolerability and QoL for tri-weekly administration. esmoopen.com/article/S2059-7…
1
8
20
3,330
Mar 18
Ph3 trial of infigratinib vs gem/cis in advanced CCA with FGFR2 fusion/rearrangement: results & reflections on early termination of PROOF 301 in @ESMO_Open. 48/300 randomized pts in >3yrs. New frameworks needed to assess therapies in ultra-rare tumors. esmoopen.com/article/S2059-7…
2
16
37
6,423
Mar 18
TBCRC 035: randomized ph II pharmacodynamic study of standard and reduced-dose palbociclib with ET in HR previously treated metastatic BC in @ESMO_Open. Lower dose of palbociclib may reduce severe neutropenia without compromising molecular response. esmoopen.com/article/S2059-7…
1
21
31
7,694
ESMO Open retweeted
Feb 25
ctDNA clearance may serve as a promising predictor of treatment response—not only in neoadjuvant chemotherapy, but also in neoadjuvant endocrine therapy.
As MRD assays continue to evolve and our therapeutic strategies advance, the potential to refine risk stratification and personalize care in early breast cancer keeps expanding. The development of liquid biopsy–guided decision-making is just getting started. @ESMO_Open
esmoopen.com/article/S2059-7…
1
7
25
3,324
ESMO Open retweeted
Feb 26
Pleased to share analysis of early endpoints in KEYNOTE585 @myESMO @ESMO_Open.
pCR, mPR, and downstaging showed associations with favorable EFS and OS in gastric/GEJ adenocarcinoma treated with perioperative pembro chemo. Further validation is warranted. sciencedirect.com/science/ar…
3
21
68
5,183
ESMO Open retweeted
👉How do we combine #TKIs with various forms of #radiotherapy in #NSCLC? When should we interrupt or modify their dose?
💡Just out in @ESMO_Open a collaborative effort between @myESMO and @estro with recommendations for #EGFR, #ALK and #BRAF/MEK inhinitors
Happy to have contributed to this practical guide for clinicians
Link to the article: kwnsfk27.r.eu-west-1.awstrac…
#LCSM @IASLC @ASCO
@OncoAlert @OncBrothers
@oncodaily @MedscapeOnc @VJOncology @Peerview
@EGFRResisters @EgfrUk @EGFRmNSCLC
@YoungLungCancer @ALKPositiveinc
1
26
49
3,652
Mar 2
PFS2 as a surrogate endpoint for OS in breast cancer randomized controlled clinical trials in @ESMO_Open. Context-dependent association, stronger association with higher PFS2 maturity and OS information fraction. esmoopen.com/article/S2059-7…
1
30
70
6,119
Mar 2
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-7…
1
63
159
15,967
Feb 23
A novel BRCAm classification system reveals differential responses to PARP inhibition and prognostic outcomes in eOC: a multicenter study in @ESMO_Open. New BRCA1m classification system identifies superior PARPi response in DBD/DBD-BRCT region. esmoopen.com/article/S2059-7…
17
41
4,499
Feb 23
ctDNA in neoadjuvant endocrine therapy for early BC in @ESMO_Open. ctDNA detection before & after neoadjuvant endocrine therapy predicts tumor burden & long-term recurrence risk. Tissue-free ctDNA assays may guide surgery & treatment decisions! esmoopen.com/article/S2059-7…
2
11
25
3,147